Brokerages Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $6.00

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have received an average recommendation of “Hold” from the six analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $6.00.

A number of research analysts have commented on the company. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of TScan Therapeutics in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Wedbush restated an “outperform” rating and issued a $5.00 target price on shares of TScan Therapeutics in a research note on Tuesday.

TScan Therapeutics Trading Up 15.3%

Shares of TCRX stock opened at $0.97 on Wednesday. The firm’s 50 day moving average price is $1.06 and its two-hundred day moving average price is $1.05. The company has a quick ratio of 6.65, a current ratio of 6.65 and a debt-to-equity ratio of 0.34. TScan Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $2.57. The stock has a market cap of $63.31 million, a price-to-earnings ratio of -1.01 and a beta of 1.03.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, hitting analysts’ consensus estimates of ($0.22). The company had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $2.50 million. TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%. On average, analysts anticipate that TScan Therapeutics will post -1.11 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Aberdeen Group plc raised its holdings in TScan Therapeutics by 31.8% in the fourth quarter. Aberdeen Group plc now owns 1,785,241 shares of the company’s stock valued at $1,785,000 after acquiring an additional 430,421 shares in the last quarter. Renaissance Technologies LLC raised its holdings in TScan Therapeutics by 37.5% in the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock valued at $1,141,000 after acquiring an additional 311,150 shares in the last quarter. Jane Street Group LLC raised its holdings in TScan Therapeutics by 377.5% in the fourth quarter. Jane Street Group LLC now owns 388,284 shares of the company’s stock valued at $388,000 after acquiring an additional 306,968 shares in the last quarter. Marshall Wace LLP raised its holdings in TScan Therapeutics by 627.5% in the fourth quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock valued at $339,000 after acquiring an additional 292,610 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in TScan Therapeutics by 1,142.5% in the fourth quarter. XTX Topco Ltd now owns 219,001 shares of the company’s stock valued at $219,000 after acquiring an additional 201,375 shares in the last quarter. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.